TapewireFind a company

person · Reporting owner

BARBERICH TIMOTHY J

Disclosed activity across 5 companies

Tapewire entity
95963
SEC CIK
0001120355

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
GI DYNAMICS, INC.GID · Entity 141502DirectorDecember 16, 2019December 18, 2019
Korro Bio, Inc.FREQ · Entity 6388DirectorAugust 17, 2022August 19, 2022
ROCKET PHARMACEUTICALS, INC.ITEK · Entity 5627DirectorJune 20, 2017June 21, 2017
TScan Therapeutics, Inc.TCRX · Entity 7255DirectorDecember 18, 2023December 21, 2023
Verastem, Inc.VSTM · Entity 5242DirectorJune 28, 2021June 30, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

GI DYNAMICS, INC.

Report date December 16, 2019 · Filed December 18, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2029-12-16Direct30,000 Reported balance After 2019-12-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2019-12-16 · Grant · Acquired 30,000 · Balance 30,000

F1: The stock option grant was approved by the Issuer's board of directors on October 29, 2019, subject to stockholder approval, and by the stockholders of the Issuer on December 16, 2019. The stock options will fully vest on October 29, 2020. In the event of a change of control of the Issuer prior to October 29, 2020, the stock options will become vested in full.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option grant was approved by the Issuer's board of directors on October 29, 2019, subject to stockholder approval, and by the stockholders of the Issuer on December 16, 2019. The stock options will fully vest on October 29, 2020. In the event of a change of control of the Issuer prior to October 29, 2020, the stock options will become vested in full.

Korro Bio, Inc.

Report date August 17, 2022 · Filed August 19, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2030-06-10Direct14,846 Reported balance After 2022-08-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2022-08-17 · Grant · Acquired 14,846 · Balance 14,846

F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options.

F1: The option vested in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders.

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $18.63 · Expires 2030-06-10Direct0 Reported balance After 2022-08-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2022-08-17 · Disposition to issuer · Disposed 14,846 · Balance 0

F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options.

F3: The option vests in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders.

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-06-16Direct14,846 Reported balance After 2022-08-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2022-08-17 · Grant · Acquired 14,846 · Balance 14,846

F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options.

F4: The option vested in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.14 · Expires 2031-06-16Direct0 Reported balance After 2022-08-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2022-08-17 · Disposition to issuer · Disposed 14,846 · Balance 0

F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options.

F5: The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.

Filing footnotes · ownership attribution and instrument terms

F1: The option vested in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders.

F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options.

F3: The option vests in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders.

F4: The option vested in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.

F5: The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.

ROCKET PHARMACEUTICALS, INC.

Report date June 20, 2017 · Filed June 21, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2027-06-19Direct45,000 Reported balance After 2017-06-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2017-06-20 · Grant · Acquired 45,000 · Balance 45,000

F1: This stock option award was issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan. The option shall vest in equal quarterly installments at the end of each quarter following June 20, 2017, subject to continued service through such dates.

Filing footnotes · ownership attribution and instrument terms

F1: This stock option award was issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan. The option shall vest in equal quarterly installments at the end of each quarter following June 20, 2017, subject to continued service through such dates.

TScan Therapeutics, Inc.

Report date December 18, 2023 · Filed December 21, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Voting Common StockSEC Table I · non-derivativeDirect67,027 Ending reported balance After 2023-12-19 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2023-12-18 · Purchase · Acquired 28,830 · Balance 66,710

F1: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $4.63 to $5.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

Row 2 · 2023-12-19 · Purchase · Acquired 317 · Balance 67,027

Voting Common StockSEC Table I · non-derivativeIndirectBy Barberich Family Trust33,259 Reported balance Holding disclosure · report date 2023-12-18 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 33,259

F2: These shares are held in a trust for the benefit of the Reporting Person's children. The Reporting Person's spouse is the grantor of the trust and retains certain rights to remove and replace the trustee of the trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $4.63 to $5.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F2: These shares are held in a trust for the benefit of the Reporting Person's children. The Reporting Person's spouse is the grantor of the trust and retains certain rights to remove and replace the trustee of the trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Verastem, Inc.

Report date June 28, 2021 · Filed June 30, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16 · Expires 2031-06-28Direct25,000 Reported balance After 2021-06-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2021-06-28 · Grant · Acquired 25,000 · Balance 25,000

F1: The stock option vests in twelve equal month installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) beginning on the on the last day of each month over a period from June, 2021 to May, 2022, provided that the Reporting Person continues to serve as a director of the Company on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests in twelve equal month installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) beginning on the on the last day of each month over a period from June, 2021 to May, 2022, provided that the Reporting Person continues to serve as a director of the Company on each such vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
December 19, 2023 Filed Dec 21, 2023 17:00 UTC TScan Therapeutics, Inc. TCRX · Entity 7255 PurchaseVoting Common Stock 317 $4.97 $1,575.01
Disclosure

SEC source: 0000950170-23-072291 · ownership.xml · nonDerivative · entry 2

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,027

Read SEC document
December 18, 2023 Filed Dec 21, 2023 17:00 UTC TScan Therapeutics, Inc. TCRX · Entity 7255 PurchaseVoting Common Stock 28,830 $4.89 $140,880.68
Disclosure

SEC source: 0000950170-23-072291 · ownership.xml · nonDerivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,710

F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $4.63 to $5.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

Read SEC document
June 13, 2023 Filed Jun 15, 2023 18:25 UTC TScan Therapeutics, Inc. TCRX · Entity 7255 GrantStock Option (Right to Buy) · Derivative 35,000 $0.00 Strike: $2.66 $0.00
Disclosure

SEC source: 0000899243-23-015646 · doc4.xml · derivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Voting Common Stock · 35,000 shares

Expires 2033-06-12

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 13, 2024 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.

Read SEC document
June 02, 2023 Filed Jun 6, 2023 19:53 UTC TScan Therapeutics, Inc. TCRX · Entity 7255 PurchaseVoting Common Stock 37,880 $2.63 $99,563.79
Disclosure

SEC source: 0000899243-23-014618 · doc4.xml · nonDerivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,880

F1 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $2.60 to $2.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · balance_after: The Reporting Person's prior reports inadvertently included 33,259 shares of the Issuer's Voting Common Stock held by the Barberich Family Trust as directly owned by the Reporting Person. These shares are held in a trust for the benefit of the Reporting Person's children. The Reporting Person's spouse is the grantor of the trust and retains certain rights to remove and replace the trustee of the trust. The Reporting Person disclaims beneficial ownership of these shares.

Read SEC document
August 17, 2022 Filed Aug 19, 2022 16:09 UTC Korro Bio, Inc. FREQ · Entity 6388 Disposition to issuerStock Option · Derivative 14,846 Not disclosed Strike: $10.14 Not disclosed
Disclosure

SEC source: 0001127602-22-021382 · form4.xml · derivative · entry 4

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,846 shares

Expires 2031-06-16

F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options.

F5 · derivative.exercise_date: The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.

Read SEC document
August 17, 2022 Filed Aug 19, 2022 16:09 UTC Korro Bio, Inc. FREQ · Entity 6388 GrantStock Option · Derivative 14,846 Not disclosed Strike: $2.14 Not disclosed
Disclosure

SEC source: 0001127602-22-021382 · form4.xml · derivative · entry 3

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,846

Underlying: Common Stock · 14,846 shares

Expires 2031-06-16

F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options.

F4 · derivative.exercise_date: The option vested in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.

Read SEC document
August 17, 2022 Filed Aug 19, 2022 16:09 UTC Korro Bio, Inc. FREQ · Entity 6388 Disposition to issuerStock Option · Derivative 14,846 Not disclosed Strike: $18.63 Not disclosed
Disclosure

SEC source: 0001127602-22-021382 · form4.xml · derivative · entry 2

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,846 shares

Expires 2030-06-10

F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options.

F3 · derivative.exercise_date: The option vests in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders.

Read SEC document
August 17, 2022 Filed Aug 19, 2022 16:09 UTC Korro Bio, Inc. FREQ · Entity 6388 GrantStock Option · Derivative 14,846 Not disclosed Strike: $2.14 Not disclosed
Disclosure

SEC source: 0001127602-22-021382 · form4.xml · derivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,846

Underlying: Common Stock · 14,846 shares

Expires 2030-06-10

F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options.

F1 · derivative.exercise_date: The option vested in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders.

Read SEC document
June 21, 2022 Filed Jun 23, 2022 16:15 UTC Korro Bio, Inc. FREQ · Entity 6388 GrantStock Option · Derivative 14,846 $0.00 Strike: $1.17 $0.00
Disclosure

SEC source: 0001127602-22-018034 · form4.xml · derivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,846

Underlying: Common Stock · 14,846 shares

Expires 2032-06-20

F1 · derivative.exercise_date: The option vests in full on the earlier of June 21, 2023 or the day immediately prior to the company's 2023 annual meeting of shareholders.

Read SEC document
June 01, 2022 Filed Jun 3, 2022 16:30 UTC TScan Therapeutics, Inc. TCRX · Entity 7255 GrantStock Option (Right to Buy) · Derivative 9,146 $0.00 Strike: $3.17 $0.00
Disclosure

SEC source: 0000899243-22-020964 · doc4.xml · derivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,146

Underlying: Voting Common Stock · 9,146 shares

Expires 2032-05-31

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 1, 2023 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.

Read SEC document
July 20, 2021 Filed Jul 22, 2021 07:43 UTC TScan Therapeutics, Inc. TCRX · Entity 7255 ConversionSeries B Preferred Stock · Derivative 33,259 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-029440 · doc4.xml · derivative · entry 2

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Voting Common Stock · 33,259 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series B Preferred Stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date.

F1 · price: Each share of the Issuer's Series B Preferred Stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series B Preferred Stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series B Preferred Stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date.

Read SEC document
July 20, 2021 Filed Jul 22, 2021 07:43 UTC TScan Therapeutics, Inc. TCRX · Entity 7255 ConversionVoting Common Stock 33,259 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-21-029440 · doc4.xml · nonDerivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,259

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series B Preferred Stock automatically converted on a one for one basis into Voting Common Stock immediately prior to the closing of the Issuer's initial public offering, without payment or further consideration. The preferred stock had no expiration date.

Read SEC document
June 28, 2021 Filed Jun 30, 2021 13:57 UTC Verastem, Inc. VSTM · Entity 5242 GrantStock Option (right to buy) · Derivative 25,000 $0.00 Strike: $4.16 $0.00
Disclosure

SEC source: 0001104659-21-087400 · tm2121071-2_4seq1.xml · derivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2031-06-28

F1 · derivative.exercise_date: The stock option vests in twelve equal month installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) beginning on the on the last day of each month over a period from June, 2021 to May, 2022, provided that the Reporting Person continues to serve as a director of the Company on each such vesting date.

Read SEC document
June 17, 2021 Filed Jun 21, 2021 16:27 UTC Korro Bio, Inc. FREQ · Entity 6388 GrantStock Option · Derivative 14,846 $0.00 Strike: $10.14 $0.00
Disclosure

SEC source: 0001127602-21-020402 · form4.xml · derivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,846

Underlying: Common Stock · 14,846 shares

Expires 2031-06-16

F1 · derivative.exercise_date: The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.

Read SEC document
December 24, 2020 Filed Feb 3, 2021 17:38 UTC Korro Bio, Inc. FREQ · Entity 6388 GiftCommon Stock 102,089 $0.00 $0.00
Disclosure

SEC source: 0001127602-21-003776 · form5.xml · nonDerivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Read SEC document
December 04, 2020 Filed Dec 7, 2020 11:15 UTC Verastem, Inc. VSTM · Entity 5242 PurchaseCommon Stock 50,000 $2.17 $108,500.00
Disclosure

SEC source: 0000904454-20-000803 · edgar.xml · nonDerivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 218,000

Read SEC document
June 16, 2020 Filed Jun 18, 2020 17:22 UTC Verastem, Inc. VSTM · Entity 5242 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $1.77 $0.00
Disclosure

SEC source: 0000904454-20-000400 · edgar.xml · derivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2030-06-16

F1 · derivative.exercise_date: The option vests in twelve equal monthly installments (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which the remaining unvested portion shall vest), beginning on June 30, 2020 and ending on May 31, 2021, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date.

Read SEC document
June 11, 2020 Filed Jun 12, 2020 07:21 UTC Korro Bio, Inc. FREQ · Entity 6388 GrantStock Option · Derivative 14,846 $0.00 Strike: $18.63 $0.00
Disclosure

SEC source: 0001127602-20-019479 · form4.xml · derivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,846

Underlying: Common Stock · 14,846 shares

Expires 2030-06-10

F1 · derivative.exercise_date: The option vests in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders.

Read SEC document
December 16, 2019 Filed Dec 18, 2019 15:05 UTC GI DYNAMICS, INC. GID · Entity 141502 GrantStock Option (right to buy) · Derivative 30,000 $0.00 Strike: $1.34 $0.00
Disclosure

SEC source: 0001213900-19-026430 · ownership.xml · derivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2029-12-16

F1 · derivative.exercise_date: The stock option grant was approved by the Issuer's board of directors on October 29, 2019, subject to stockholder approval, and by the stockholders of the Issuer on December 16, 2019. The stock options will fully vest on October 29, 2020. In the event of a change of control of the Issuer prior to October 29, 2020, the stock options will become vested in full.

Read SEC document
October 07, 2019 Filed Oct 7, 2019 20:31 UTC Korro Bio, Inc. FREQ · Entity 6388 ConversionSeries C Preferred Stock · Derivative 63,698 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-025216 · doc4.xml · derivative · entry 5

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,457 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077 for one basis.

F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077 for one basis.

F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077 for one basis.

F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077 for one basis.

Read SEC document
October 07, 2019 Filed Oct 7, 2019 20:31 UTC Korro Bio, Inc. FREQ · Entity 6388 ConversionSeries B Preferred Stock · Derivative 543,219 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-025216 · doc4.xml · derivative · entry 4

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · The Barberich Family Trust

Disclosed balance after: 0

Underlying: Common Stock · 80,650 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077 for one basis.

F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077 for one basis.

F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077 for one basis.

F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077 for one basis.

Read SEC document
October 07, 2019 Filed Oct 7, 2019 20:31 UTC Korro Bio, Inc. FREQ · Entity 6388 ConversionSeries A Preferred Stock · Derivative 506,278 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-025216 · doc4.xml · derivative · entry 3

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 75,165 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077 for one basis.

F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077 for one basis.

F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077 for one basis.

F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077 for one basis.

Read SEC document
October 07, 2019 Filed Oct 7, 2019 20:31 UTC Korro Bio, Inc. FREQ · Entity 6388 ConversionCommon Stock 80,650 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-025216 · doc4.xml · nonDerivative · entry 2

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · The Barberich Family Trust

Disclosed balance after: 80,650

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077 for one basis.

F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077 for one basis.

Read SEC document
October 07, 2019 Filed Oct 7, 2019 20:31 UTC Korro Bio, Inc. FREQ · Entity 6388 ConversionCommon Stock 84,622 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-025216 · doc4.xml · nonDerivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,089

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077 for one basis.

F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.148467077 for one basis.

Read SEC document
June 21, 2019 Filed Jun 25, 2019 21:38 UTC Verastem, Inc. VSTM · Entity 5242 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $1.81 $0.00
Disclosure

SEC source: 0001104659-19-037498 · a4.xml · derivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2029-06-21

F1 · derivative.exercise_date: The option vests in twelve equal monthly installments (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which the remaining unvested portion shall vest), beginning on 7/21/2019 and ending on 06/21/2020, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date.

Read SEC document
March 15, 2019 Filed Mar 19, 2019 16:12 UTC Verastem, Inc. VSTM · Entity 5242 PurchaseCommon Stock 33,000 $3.21 $105,930.00
Disclosure

SEC source: 0000904454-19-000333 · edgar.xml · nonDerivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 168,000

Read SEC document
September 28, 2018 Filed Oct 2, 2018 19:16 UTC Verastem, Inc. VSTM · Entity 5242 PurchaseCommon Stock 5,000 $7.31 $36,550.00
Disclosure

SEC source: 0000904454-18-000635 · edgar.xml · nonDerivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,000

Read SEC document
June 11, 2018 Filed Feb 13, 2019 16:48 UTC Verastem, Inc. VSTM · Entity 5242 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $5.59 $0.00
Disclosure

SEC source: 0000904454-19-000223 · edgar.xml · derivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2028-06-11

F1 · derivative.exercise_date: The option vests in twelve equal monthly installments (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which the remaining unvested portion shall vest), beginning on 7/11/2018 and ending on 06/11/2019, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date.

Read SEC document
December 05, 2017 Filed Dec 7, 2017 16:02 UTC Verastem, Inc. VSTM · Entity 5242 PurchaseCommon Stock 60,538 $3.95 $239,125.10
Disclosure

SEC source: 0001104659-17-072297 · a4.xml · nonDerivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,000

F1 · price: The price reported in column 4 is a weighted average priced. These shares were purchased in multiple transactions at prices ranging from $3.80 to $4.01. Upon request by the staff of the Securities and Exchange Commission, the Issuer, or security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Read SEC document
June 20, 2017 Filed Jun 21, 2017 16:11 UTC ROCKET PHARMACEUTICALS, INC. ITEK · Entity 5627 GrantStock Options (Right to Buy) · Derivative 45,000 $0.00 Strike: $1.80 $0.00
Disclosure

SEC source: 0000899243-17-016842 · doc4.xml · derivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2027-06-19

F1 · derivative.exercise_date: This stock option award was issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan. The option shall vest in equal quarterly installments at the end of each quarter following June 20, 2017, subject to continued service through such dates.

Read SEC document
June 13, 2017 Filed Jun 15, 2017 16:22 UTC Verastem, Inc. VSTM · Entity 5242 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $2.09 $0.00
Disclosure

SEC source: 0001104659-17-039561 · a4.xml · derivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2027-06-13

F1 · derivative.exercise_date: This option will vest in twelve monthly installments through June 13, 2018, with the first monthly installment vesting on July 13, 2017.

Read SEC document
May 15, 2017 Filed May 17, 2017 08:21 UTC Verastem, Inc. VSTM · Entity 5242 PurchaseCommon Stock 30,000 $2.45 $73,500.00
Disclosure

SEC source: 0001104659-17-033344 · a4.xml · nonDerivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,462

F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.42 to $2.49, inclusive. Upon request by the staff of the Securities and Exchange Commission, the Issuer, or security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price.

Read SEC document
September 28, 2016 Filed Sep 29, 2016 07:46 UTC ROCKET PHARMACEUTICALS, INC. ITEK · Entity 5627 GrantStock Options (Right to Buy) · Derivative 24,000 $0.00 Strike: $9.49 $0.00
Disclosure

SEC source: 0000899243-16-030296 · doc4.xml · derivative · entry 1

BARBERICH TIMOTHY J · CIK 0001120355 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,000

Underlying: Common Stock · 24,000 shares

Expires 2026-09-28

F1 · derivative.exercise_date: This stock option award was issued pursuant to Issuer's 2014 Stock Option and Incentive Plan and shall vest as follows: 25% of the shares shall be vested on September 28, 2017 and 1/36th of the remaining shares shall vest on each monthly anniversary thereafter, subject to Reporting Person's continued service as a director of the Issuer.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.